Enhanced Vascular Endothelial NLRP3 Inflammasome Activation by Plasma Exosomes from Liver‐specific Acid Ceramidase Gene Knockout Mice on the High Fat Diet

Abstract

Circulatory exosomes have been reported to induce vascular endothelial injury and neointima proliferation in mice with liver‐specific deletion of acid ceramidase gene (Asah1fl/fl/Albcre, Asah1 is mouse code of this gene). However, the precise mechanism mediating this exosome‐induced endothelial injury remains unknown. The present study tested a hypothesis that plasma exosomes from Asah1fl/fl/Albcre mice on the high fat diet (HFD) activate endothelial NLRP3 inflammasome activation leading to endothelial dysfunction. To test this hypothesis, wild type (WT/WT) mice and Asah1fl/fl/Albcre mice were fed with normal diet (ND) or HFD for 2 months. Using immunofluorescence confocal microscopy, we confirmed that ceramide levels significantly increased in the liver of Asah1fl/fl/Albcre mice compared to its WT/WT littermates and that HFD further enhanced lysosome ceramide levels in the liver as shown by the colocalization of ceramide with lysosome marker, lamp‐1. Then, isolated exosomes from the plasma of these mice were used to treat the primary cultured WT/WT endothelial cells from the carotid artery. It was found that exosomes isolated from HFD‐treated mice (HFD‐Exo) even from WT/WT mice significantly stimulated NLRP3 inflammasome formation and activation as shown by the significant increases in the colocalization of NLRP3 with Caspase‐1 or ASC, caspase‐1 activity and interleukin 1 beta (IL‐1β) level in the endothelial cells compared to exosomes from ND treated mice (ND‐Exo). This inflammasome formation and activation were remarkably enhanced if endothelial cells were treated by HFD‐Exo isolated from Asah1fl/fl/Albcre mice. To confirm whether lysosomal ceramide contributes to HFD‐Exo‐induced endothelial NLRP3 inflammasome activation, we further treated endothelial cells with C(2)‐ceramide, which was shown similar effects comparable to that induced by HFD‐Exo. Using dibutyryl‐cAMP, a blocker of ceramide‐induced action significantly attenuated C(2)‐ceramide‐ or HDF‐Exo‐induced enhancement of endothelial NLRP3 inflammmasome activation. Together, these results suggest that liver‐specific deletion of lysosomal Asah1 gene promotes release of HFD‐Exos that may contain high ceramide, activating endothelial NLRP3 inflammasome and thereby resulting in endothelial dysfunction during HFD‐induced liver steatosis.